The consolidated litigations underway in Pennsylvania and Louisiana were established to allow Xarelto lawsuits that put forth similar allegations of fact to move more efficiently through the court system.
New York, New York (PRWEB) April 23, 2015
The products liability litigation involving Xarelto (http://www.xareltolawsuit2015.com/) continues to grow, as court records indicate that dozens of new lawsuits were filed in state and federal proceedings over the past month. According to an updated docket report issued by the U.S. Judicial Panel on Multidistrict Litigation on April 17th, 402 Xarelto lawsuits are now pending in a multidistrict litigation underway in U.S. District Court, Eastern District of Louisiana, where all federally filed claims involving the blood thinner have been consolidated for coordinated pretrial proceedings. Court records indicate that this represents an increase of about 100 cases since March 16th, when the Panel issued its previous report. (In Re: Xarelto Products Liability Litigation, No. 2592)
A Case List released by Pennsylvania’s Philadelphia Court of Common Pleas on April 23rd shows that at least 204 Xarelto lawsuits are currently pending in the state’s mass tort proceeding. According to court documents, some 50 new filings were added to the proceeding in March. (In Re: Xarelto Litigation, Case ID 150102349)
“Our Firm is representing a number of Xarelto plaintiffs in U.S. courts who allegedly suffered serious internal bleeding and other complications related to its use. We also continue to receive inquiries from potential plaintiffs who claim to have experienced similar injuries, so we are not at all surprised that these lawsuits continue to mount,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs.
Xarelto Lawsuit Allegations
Xarelto (rivaroxaban) was approved by the U.S. Food & Drug Administration in 2011, and is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery.*
All of the Xarelto lawsuits currently pending in the state and federal litigations involve similar allegations regarding its association with serious internal bleeding and related complications, including stroke, deep vein thrombosis and pulmonary embolism. Plaintiffs further allege that the medication was wrongly marketed as an improvement over warfarin, and point out that bleeding associated with this much older blood thinner can be stopped via the administration of vitamin K. The complaints further note that during its first full year on the market, Xarelto was named in 2,081 adverse event reports submitted to the FDA, including at least 151 deaths. By contrast, warfarin was named in only 861 adverse event reports, including 56 fatalities, during the same period.***
“The consolidated litigations underway in Pennsylvania and Louisiana were established to allow Xarelto lawsuits that put forth similar allegations of fact to move more efficiently through the court system. Considering the number of new filings both proceedings have seen in the past month, it appears that the consolidation of these claims was well warranted,” says Sandy A. Liebhard.
Xarelto patients who allegedly experienced life-threatening episodes of internal bleeding and other complications related to its use may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014
**ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP